控释格列吡嗪治疗2型糖尿病的临床研究

目的：研究控释格列吡嗪对2型糖尿病病人血糖、血脂、糖化血红蛋白及空腹胰岛素的影响并与即释格列吡嗪比较。方法：符合1999年WHO制订的诊断标准60例2型糖尿病人随机分为2组：治疗组：服用控释格列吡嗪5～15mg／天共38人：对照组：服用即释格列吡嗪15～30mg／天，共22人。在治疗过程中观察血糖的动态变化，治疗前治疗后分别测定糖化血红蛋白，甘油三酯、胆固醇、空腹胰岛素水平，观察治疗效果。结果：治疗纽和对照纽均明显降低血糖、糖化血红蛋白水平，并对胆固醇、甘油三酯有降低趋势，对照组明显增加空腹胰岛素水平，而控释片则没有明显增加的作用。结论：控释格列吡嗪能够即较好的降低血糖、改善脂代谢，没有明显增加血胰岛素水平，具有改善胰岛素抵抗的作用。

The clinical study on treating type 2 diabetes mellitus with glipizide

Objective： To study on effects of control-released glipizide on serum glucose, HbA1c, cholesterol, triglyceride, fasting insulin level and compare with the result of immediate-released glipizide treatment. Methods： 60 patients who were chosen according the WHO 1999 criterion were divided 2 group： treatment group, 38 patients, were given control-released glipizide 5-15 mg/day; control group, 22 patients, were administrated immediate-released glipizide 15-30mg/day. The level of serum glucose, HbA1c, cholesterol, triglyceride and fasting insulin were detected. Results： The two type drugs all decreased the concentration of serum glucose ＆ HbAlc obviously, declined the level of cholesterol, triglyceride lightly, immediate-released glipizide increased the concentration of fasting insulin, but not in control-releasing glipizide group. Conclusion： Control-releasing glipizide satisfactorily decreased glucose level, approved lipid metabolism, at the same time, didn＇t increase fasting insulin concentration.